Development and Validation of a Real-time Prediction Model for Acute Kidney Injury in Hospitalized Patients
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Sep 12, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating and testing a new tool that can help predict acute kidney injury (AKI) in hospitalized patients. AKI is a condition where the kidneys suddenly stop working well, and catching it early can help prevent serious problems. The researchers have developed a simple and easy-to-understand model that can be used in hospitals to identify patients at risk of AKI. They are testing this model in multiple hospitals in China to ensure it works well in different settings.
To be eligible for this trial, participants need to be adults aged 18 and older who are being treated in one of the five participating hospitals. However, individuals with certain conditions, such as those on dialysis or with advanced kidney disease, won't be able to join. If you participate, you can expect to have your kidney function monitored through regular blood tests during your hospital stay. This study is an important step toward improving kidney care for patients in developing countries, and it aims to make hospital stays safer for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (18 years and older) admitted to five hospitals during the study period
- Exclusion Criteria:
- • Have less than 2 documented serum creatinine (Scr) measurements during hospitalization
- • Being diagnosed with end-stage renal disease (ESRD)
- • Maintained on dialysis or had an initial Scr greater than or equal to 4.0 mg/dL at admission
- • Developed AKI prior to admission or within 24 hours after admission
- • Length of stay shorter than 24 hours
- • Underwent kidney transplantation or nephrectomy during hospitalization
- • With all Scr measurements lower than or equal to 0.6 mg/dL from 90 days prior to admission until discharge.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Li Yang
Study Director
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported